A Study on the action mechanism of Ebastine for chronic urticaria and efficacy and safety in the long term follow-up trial

A Study on the action mechanism of Ebastine for chronic urticaria and efficacy and safety in the long term follow-up trial - Trial of Ebastine for chronic urticaria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006028

Enrollment

Registered

2011-09-01

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic urticaria

Interventions

8 week-treatment with ebastine(10mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as chronic urticaria 1) patients of the level 3 patients or higher defined by Guidelines for the Diagnosis and Treatment of Urticaria and Angioedema 2) Patients who gave their written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients complicated with a skin disorder blocking response evaluation 2) Patients who do not avoid continual use of drugs interrupting response evaluation (antiallergics, oral steroids, immunosuppressives) , except for patients who do not have a plan to change the of the drug dosage during the trial 3) Patients with severe complications including hepatic disease, renal disease, cardiac disease 4) Patients with pregnancy, its chance, and lactation 5) Patients receiving hyposensitization therapy 6) Patients taking antihistamines during 4 weeks before starting the trial 7) Patients whom doctors regarded inappropriate for the trial

Design outcomes

Primary

Measure	Time frame
1) Quantification of Histamine H1 receptor mRNA 2) Enhancement of skin conditions 3) With or without relapse 4) Improvement of Patients QOL	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026